LEADER 01572nam  2200517 a 450 
001 9910790191703321
005 20200520144314.0
010   $a1-62081-045-X
035   $a(CKB)2670000000160380
035   $a(EBL)3021072
035   $a(SSID)ssj0000688574
035   $a(PQKBManifestationID)12238843
035   $a(PQKBTitleCode)TC0000688574
035   $a(PQKBWorkID)10607652
035   $a(PQKB)11646848
035   $a(MiAaPQ)EBC3021072
035   $a(Au-PeEL)EBL3021072
035   $a(CaPaEBR)ebr10681272
035   $a(OCoLC)841169033
035   $a(EXLCZ)992670000000160380
100   $a20110322d2011      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aDNA vaccines$b[electronic resource] $etypes, advantages and limitations /$fErin C. Donnelly and Arthur M. Dixon, editors
210   $aHauppauge, N.Y. $cNova Science$dc2011
215   $a1 online resource (214 p.)
225 1 $aImmunology and immune system disorders
300   $aDescription based upon print version of record.
311   $a1-61324-444-4 
320   $aIncludes bibliographical references and index.
410  0$aImmunology and immune system disorders.
606   $aDNA vaccines
615  0$aDNA vaccines.
676   $a615/.372
701   $aDonnelly$b Erin C$01523662
701   $aDixon$b Arthur M$01523663
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910790191703321
996   $aDNA vaccines$93763956
997   $aUNINA